Mycenax Biotech Inc.

NT$20.70As of Sun 8 Nov 2026, 12:00 UTC
TPEx:4726Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR (5.66%)
Div yield —
ROE (24.06%)
Biotechnology
Beta (5Y) 0.47
PE TTM —
TSR TTM (38.48%)
Mkt cap NT$4.286B
ROIC (8.44%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$25
21.42%
(41.70%)
Hold 7|6|6|5|11
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.29
0.32
0.32
0.35
8.81%
15.45%
11.89%
20.53%
RevenueNT$M
218.8
214.0
212.1
222.2
2.44%
(3.58%)
(3.50%)
(1.13%)
Peers (US$129.4M)
Cap (US$)
PE
133.6M
—
Capital
TTM
5Y
10Y
Leveragex
2.468
(0.020)
(0.011)
EBIT/Intx
1.023
0.490
0.488
Own earn%
(77.13)
(13.93)
(13.76)
Sh yield%
11.30
13.46
11.04
Owners
Insiders/Inst%
14.82
68.16
Short interest%
5.78
SBC / revenue%
0.33
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
19–24
$1 testx
−0.1
Incr. ROIC%
13